Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Cantor Fitzgerald
Healthtrust
Citi
Moodys

Generated: March 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Obinutuzumab

« Back to Dashboard

US Patents for Obinutuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obinutuzumab ➤ Sign Up Antibody targeting cell surface deposited complement protein C3d and use thereof The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) ➤ Sign Up
Obinutuzumab ➤ Sign Up Salts and solid form of a BTK inhibitor PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) ➤ Sign Up
Obinutuzumab ➤ Sign Up Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione Celgene Corporation (Summit, NJ) ➤ Sign Up
Obinutuzumab ➤ Sign Up Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality Genentech, Inc. (South San Francisco, CA) ➤ Sign Up
Obinutuzumab ➤ Sign Up Antibody-SN-38 immunoconjugates with a CL2A linker Immunomedics, Inc. (Morris Plains, NJ) ➤ Sign Up
Obinutuzumab ➤ Sign Up Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY) ➤ Sign Up
Obinutuzumab ➤ Sign Up Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) ➤ Sign Up
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Obinutuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Obinutuzumab Canada 2936346 2034-01-08 ➤ Sign Up
Obinutuzumab European Patent Office 3092252 2034-01-08 ➤ Sign Up
Obinutuzumab World Intellectual Property Organization (WIPO) 2015105973 2034-01-08 ➤ Sign Up
Obinutuzumab Australia 2015218713 2034-02-21 ➤ Sign Up
Obinutuzumab Canada 2939186 2034-02-21 ➤ Sign Up
Obinutuzumab China 106456652 2034-02-21 ➤ Sign Up
Obinutuzumab Eurasian Patent Organization 201691484 2034-02-21 ➤ Sign Up
Drugname Country Document Number Estimated Expiration Related US Patent

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Covington
Cantor Fitzgerald
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.